Rational Design of Novel Selective Dual-Target Inhibitors of Acetylcholinesterase and Monoamine Oxidase B as Potential Anti-Alzheimer's Disease Agents.
Acetylcholinesterase
/ metabolism
Alzheimer Disease
/ drug therapy
Animals
Blood-Brain Barrier
/ drug effects
Cholinesterase Inhibitors
/ administration & dosage
Drug Delivery Systems
/ methods
Drug Design
Mice
Mice, Inbred ICR
Monoamine Oxidase
/ metabolism
Monoamine Oxidase Inhibitors
/ administration & dosage
AChE inhibitors
Alzheimer’s disease
MAO-B inhibitors
metal chelating agents
multifunctional agents
Journal
ACS chemical neuroscience
ISSN: 1948-7193
Titre abrégé: ACS Chem Neurosci
Pays: United States
ID NLM: 101525337
Informations de publication
Date de publication:
16 01 2019
16 01 2019
Historique:
pubmed:
16
8
2018
medline:
19
2
2020
entrez:
16
8
2018
Statut:
ppublish
Résumé
Multifunctional agents aiming at cholinesterases (ChEs) and monoamine oxidases (MAOs) are promising therapy for Alzheimer's disease (AD). Herein, a series of novel propargylamine-modified pyrimidinylthiourea derivatives (1-4) were designed and synthesized as dual inhibitors of ChEs and MAOs with other functions against AD. Most of these derivatives inhibited ChEs and MAOs with IC
Identifiants
pubmed: 30110536
doi: 10.1021/acschemneuro.8b00357
doi:
Substances chimiques
Cholinesterase Inhibitors
0
Monoamine Oxidase Inhibitors
0
Monoamine Oxidase
EC 1.4.3.4
Acetylcholinesterase
EC 3.1.1.7
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM